Sanofi

A lab-in-the-loop system built with AWS that gives discovery AI agents shared memory of past experiments. Sanofi aims to halve the number of molecules needing wet-lab validation.

Partners: AWS

A multi-year collaboration, first signed in December 2023, that uses Aqemia's generative AI and physics-based platform to design small molecules. It was expanded in July 2026 with a new target nomination.

Partners: Aqemia

A multi-year deal to co-develop biopharma AI agents with Owkin, backed by a five-year licence to Owkin's K Pro AI scientist.

Partners: Owkin

A tool that analyzes multimodal data to simulate trials before they start, forecasting cycle times, patient burden and cost drivers.

An in-silico trial platform built on Sanofi disease-biology models and clinical data. It is meant to predict safety, efficacy and trial outcomes to inform go/no-go decisions.

Applies AI-assisted review and validation to clinical results once data become available.

An AI tool built jointly by Formation Bio, OpenAI and Sanofi to speed up patient recruitment for clinical trials. Sanofi planned the first deployment in Phase 3 multiple sclerosis studies.

Partners: Formation Bio, OpenAI

A digital and AI solution that streamlines transfer of new drugs or indications from R&D to industrial-scale manufacturing.

A shop-floor AI solution aimed at improving equipment reliability, continuity and quality across production systems.

An AI quality-intelligence tool that began as a narrow pilot on deviation and complaint trending with suggested root causes, and is now used at several manufacturing sites.

Partners: Aily Labs

An in-house AI tool that learns from past and current batch performance to push manufacturing yields higher. Sanofi estimates about EUR 10 million a year in savings from analyzing over 13,000 Lovenox batch runs.

An AI agent used to relieve bottlenecks in quality assurance workflows.

Manufacturing staff use AI/ML to find similar past deviations across sites and to automate review and trending of minor deviations. Sanofi reported a 60% cut in closure time.

An AI tool for reviewing scientific literature. Sanofi reports accuracy above 95% and much shorter review times.

Sanofi ran a small Copilot pilot but decided not to roll it out widely to employees, according to its chief digital officer.

Partners: Microsoft

Sanofi's internally hosted generative AI companion, launched in October 2024, that helps employees find answers, navigate tools and automate routine tasks. Sanofi says it supports more than 30,000 users.

Sanofi's chief digital officer says Claude is central to its AI transformation and used daily by most employees.

Partners: Anthropic

An AI app built with Aily Labs that pulls together internal data across functions to give staff real-time views and predictions. Sanofi announced its company-wide scale-up in June 2023.

Partners: Aily Labs

An AI-powered energy management platform that helps optimize energy consumption in real time.

plai supplies predictions and what-if scenarios to the R&D governance meetings where molecule progression decisions are taken.

Partners: Aily Labs

An AI agent used to help optimize product launch plans.

Sanofi's internal platform for building AI, used by its data and AI developers.

Sanofi is moving AI workflows directly onto its Snowflake data using Cortex AI and the Elementum workflow platform, pitched as AI replacing some applications.

Partners: Snowflake, Elementum

An AI agent built on Snowflake Cortex AI that produces pre-call plans for sales reps before physician visits.

Partners: Snowflake

Sanofi says it uses machine learning and AI across R&D, including for writing clinical study reports. No tool or metrics are named on the page.

A generative AI tool that helps write Sanofi's annual product quality reviews (PQRs). In June 2025 Sanofi reported about 3,500 PQRs a year and a target to cut creation time by 70 percent. An Aug 2024 Outsourced Pharma interview with Sanofi reported PQR writing about eightfold faster, a reported result and not a target.

Sanofi's pharmacovigilance team uses AI and OCR on the IQVIA Vigilance Platform to automate intake of the more than 700,000 adverse reactions it receives each year.

Partners: IQVIA

AI-driven target discovery engines in R&D. Sanofi says they produced seven new drug targets in a single year.

An AI tool used in manufacturing and supply to help decide how production batches are allocated.

Use of plai in biopharma supply chain to flag likely low-inventory positions ahead of time so planners can act earlier.

Partners: Aily Labs

A free AI pre-diagnosis tool launched with French start-up MIS that helps doctors identify patients who may have a rare disease.

Partners: Medical Intelligence Service (MIS)